Thus, accumulating evidence indicates that higher numbers and frequencies of CD8+ T cells maintaining effector-memory properties (e.g., CD28 expression) for enhanced survival together with the ability to induce cytolytic molecules, such as perforin and granzyme B, for tumor killing would be the optimal cells to generate for melanoma TIL therapy. This evidence concerns the gene PRF1 and neoplasm.